Dab­bling in CD47, Pfiz­er in­fus­es $25M in­to a biotech play­er tout­ing pos­i­tive monother­a­py da­ta

Pfiz­er is fol­low­ing Gilead, Ab­b­Vie, Boehringer and a string of biotech up­starts in­to the CD47 race, lin­ing up its own shots at the “don’t eat me” sig­nal that is shap­ing up to be the big can­cer check­point tar­get.

And it’s start­ing small.

With $25 mil­lion in ini­tial in­vest­ment, Pfiz­er is stack­ing up about 2.3 mil­lion shares in Tril­li­um Ther­a­peu­tics $TRIL for $10.88 per share — a 15% pre­mi­um over its Fri­day close. In­vestors were quick to fol­low Pfiz­er’s lead, bid­ding up Tril­li­um’s shares 40% Wednes­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.